Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

UNI-BIO SCIENCE GROUP LIMITED
聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

VOLUNTARY ANNOUNCEMENT

UNI-BIO SCIENCE GROUP EXPANDS GLOBAL REACH OF BOGUTAI® THROUGH STRATEGIC PARTNERSHIP

Hong Kong, 12 September 2025 — The board of directors (the "**Board**") of Uni-Bio Science Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that its wholly-owned subsidiary, Beijing Genetech Pharmaceutical Co., Ltd. ("**Beijing Genetech**"), has entered into a strategic cooperation agreement with Kexing Biopharm Co., Ltd. ("**Kexing Biopharm**"). Pursuant to the agreement, Kexing Biopharm will exclusively commercialize Bogutai®, the Group's innovative osteoporosis treatment, in six countries including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico (the "**Cooperation Regions**").

Bogutai® is a next-generation osteoporosis treatment designed to promote bone formation and improve bone density. As the first domestically approved pre-filled pen-type teriparatide injection in China, Bogutai® offers patients a more convenient and comfortable treatment experience, with its ultra-fine needle and precise dosing system reducing discomfort and improving compliance. It is currently indicated for postmenopausal women at high risk of fractures, addressing a significant unmet medical need in this field.

With over 10 million osteoporosis patients across the Cooperation Regions, the partnership represents a strong opportunity to bring Bogutai® to underserved markets valued at nearly USD1.5 billion. Since its launch in China in March 2024, Bogutai® has achieved remarkable success, with a 248.9% year-on-year revenue growth in the first half of 2025. This collaboration builds on that momentum, with revenue from the new markets expected as early as late 2026 and competitive pricing positioning Bogutai® for higher profit margins.

Kexing Biopharm (Stock Code: 688136.SH) is a leading multinational innovative biopharmaceutical company. It has established and currently operates 6 overseas subsidiaries and offices, which have acquired market access and achieved sales in dozens of countries and regions around the world such as the European Union, Brazil, Philippines and Indonesia.

The Board is of the view that this collaboration constitutes a key milestone in the Group's global expansion strategy, which not only consolidates its position in the osteoporosis treatment market but also generates long-term value for shareholders.

By Order of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 12 September 2025

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman), Mr. Zhao Zhi Gang (Chief executive) and Dr. Wen Yalei (Chief Operating Officer); two non-executive Directors, Mr. Yau Kwok Wing Tony and Ms. Zhang Qing; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.